Palvella Therapeutics (PVLA) Current Leases (2021 - 2026)

Palvella Therapeutics (PVLA) posted quarterly Current Leases of $209000.0 for Q1 2026, up 3.47% quarter-over-quarter from $202000.0 in Q4 2025.

Palvella Therapeutics (PVLA) Current Leases (2021 - 2026) Analysis & Trends

Palvella Therapeutics (PVLA) has reported Current Leases for 5 consecutive years, with $209000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Current Leases changed N/A year-over-year to $209000.0; the TTM figure through Mar 2026 stood at $209000.0 (changed N/A YoY), while the FY2025 annual figure was $202000.0, changed N/A from the prior year.
Current Leases climbed to $209000.0 in Q1 2026 per PVLA's latest filing, from $202000.0 in the prior quarter.
Across five years, Current Leases topped out at $12.3 million in Q3 2023 and bottomed at $202000.0 in Q4 2025.
Historically, Current Leases has averaged $2.3 million across 4 years, with a median of $859000.0 in 2022.
Annual changes were most pronounced in 2022 — Current Leases declined 18.11% — and 2023, when it surged 1388.14%.
Palvella Therapeutics' Current Leases stood at $859000.0 in 2022, then soared by 1330.97% to $12.3 million in 2023, then slumped by 98.36% to $202000.0 in 2025, then climbed by 3.47% to $209000.0 in 2026.
Business Quant data shows PVLA's Current Leases at $209000.0 in Q1 2026, $202000.0 in Q4 2025, and $12.3 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	720.00 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	11.00 Mn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	16.75 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	21.95 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	2.24 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	45.93 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	6.27 Mn
10	Palvella Therapeutics	2.25 Bn	1.93 Bn	-	217,000.00

Download Data